1 Min In News
Follow this topic
Bookmark
Record learning outcomes
Pharmaceutical company ALK has today announced that EURneffy® 2mg nasal adrenaline spray is available for healthcare professionals to prescribe.
The UK’s first needle-free nasal adrenaline spray for anaphylaxis offers a non-invasive alterative to traditional auto-injectors (AAIs), which ALK researches shows that 88 per cent of HCPs know patients or caregivers who have been unable to use an AAI in an emergency.
EURneffy® is pocket-sized and ready-to-use, has a longer shelf life and can withstand temperature changes better than adrenaline auto-injectors – factors which could mean potential savings for the NHS, according to ALK research.
“With EURneffy® now available for prescription, we can offer an alternative, needle-free method of adrenaline delivery that may be easier for patients and families to manage and administer. The ready-to-use and portable design may help address some of the practical and psychological barriers to consistently carrying and using adrenaline auto-injectors, especially needle anxiety,” said Dr Shuaib Nasser, consultant allergist and respiratory physician and clinical lead for Allergy at Cambridge University Hospital NHS Foundation Trust.
“The pharmacological data show that EURneffy® achieves outcomes comparable to adrenaline auto-injectors, regardless of nasal congestion, leading to its approval here in the UK. What’s exciting is that we’re now also seeing the first real-world evidence, which should provide further assurance to prescribers of its interchangeability with adrenaline injection.”
This new treatment is a huge turning point for anyone who has or knows someone with life-threatening allergy. Training Matters wrote more about how EURneffy® is changing the landscape for allergy-sufferer’s in our article Shock factor.
In News